Forecast for Vaccine Stocks After Coronavirus Pandemic Passes
Stephen Gardner, director at ETF Managers Group, explains why investors shouldn't be rushing to sell vaccine stocks like Moderna or BioNTech even as the spread of COVID-19 slows down.
More Videos
Fizz, Fame & Fortune: Poppi’s Billion-Dollar Journey with CEO Allison Ellsworth
Poppi Co-Founder Allison Ellsworth shares how the prebiotic soda went from Shark Tank to a $1.95B PepsiCo deal—gut health, grit, and big brand moves.
Finally! Fed Slashes Rates, What It Means for You and Your Money
Unpacking Jerome Powell’s surprise rate cut with Tematica Research CIO Chris Versace—what it signals, who wins, who loses, and what smart investors do now.
Connecting for Survival: Objective Zero’s Mission to End Veteran Suicide
Chris and Betsey Mercado share how Objective Zero’s peer‑support app, resources & trained pathfinders are fighting veteran suicide & building community.
The Fabric of Success: BrilliA’s CEO on Innovation, IPO, and Market Leadership
Kendrew Hartanto, CEO of BrilliA (NYSE: BRIA), shares how the company stitched its path to IPO and redefined leadership in women’s undergarments.
Go Fund Yourself: From Spirited Sips to Smart Learning
Hook Hand Rum elevates your drinking experience with its very own handcrafted rum. Illoominate encourages learning and creativity for kids using AI.
The Man Studios Listen To: Kevin Goetz on Testing 3,000+ Films at Screen Engine
Kevin Goetz, CEO of Screen Engine, shares how testing 3,000+ films—including Barbie—helps studios shape stories audiences love.
